製品番号: HY-121255

(-)-Cryptopleurine

(別名: (R)-Cryptopleurine; NSC 19912)

カスタマーレビュー

Based on 1 Customer Validation

(–)-Cryptopleurine is an alkaloid that has been found in Lauraceae and has diverse biological activities. It inhibits the growth of human A375 melanoma, A431 epidermoid carcinoma, A549 lung, MES-SA uterine sarcoma, and MCF-7 breast cancer cells (IC₅₀=3 nM for all).2 (–)-Cryptopleurine inhibits hypoxia-induced gene expression in a hypoxia response element (HRE) reporter assay (IC₅₀=8.7 nM).3 (–)-Cryptopleurine (500 μg/mL) prevents lesion formation in tobacco (N. tabacum) plants infected with tobacco mosaic virus (TMV). It also inhibits protein synthesis by yeast and mammalian ribosomes.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98%
CAS 番号: 482-22-4
分子式: C₂₄H₂₇NO₃
分子量:377.48

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

(-)-Cryptopleurine 構造式

CAS 番号: 482-22-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human melanoma, A375 cells Cytotoxicity against human melanoma, A375 cells	[PMID: 16236503]
A-375	IC₅₀	1.2 nM Compound: (-)-1	Antiproliferative activity against human A375 cells after 72 hrs by ATPlite assay Antiproliferative activity against human A375 cells after 72 hrs by ATPlite assay	[PMID: 25499434]
A-431	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human epidermoid carcinoma, A431 cells Cytotoxicity against human epidermoid carcinoma, A431 cells	[PMID: 16236503]
A549	GI₅₀	<0.001 μM Compound: 36	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 22417638]
A549	GI₅₀	1.38 nM Compound: R-cryptopleurine	Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 21668000]
A549	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human lung carcinoma, A549 cells Cytotoxicity against human lung carcinoma, A549 cells	[PMID: 16236503]
A549	IC₅₀	0.94 nM Compound: 2	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 26393416]
A549	IC₅₀	1.38 nM Compound: cryptopleurine	Cytotoxicity against human A549 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis Cytotoxicity against human A549 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis	[PMID: 22823514]
A549	IC₅₀	1.9 nM Compound: (-)-1	Antiproliferative activity against human A549 cells after 72 hrs by ATPlite assay Antiproliferative activity against human A549 cells after 72 hrs by ATPlite assay	[PMID: 25499434]
A549	IC₅₀	1.9 nM Compound: cryptopleurine	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 22823514]
AGS	IC₅₀	8.7 nM Compound: 1	Inhibition of hypoxia-induced HIF1 activation in human AGS cells after 16 hrs by pGL3-HRE-luciferase reporter gene assay Inhibition of hypoxia-induced HIF1 activation in human AGS cells after 16 hrs by pGL3-HRE-luciferase reporter gene assay	[PMID: 16872154]
BT-20	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human breast carcinoma, BT20 cells Cytotoxicity against human breast carcinoma, BT20 cells	[PMID: 16236503]
BUD-8	IC₅₀	0.006 μM Compound: (-)-2	Cytotoxicity against human fibroblast, BUD8 cells Cytotoxicity against human fibroblast, BUD8 cells	[PMID: 16236503]
CAKI-1	IC₅₀	0.86 nM Compound: 2	Cytotoxicity against human Caki1 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human Caki1 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 26393416]
CL1-0	IC₅₀	5 nM Compound: cryptopleurine	Cytotoxicity against human CL1-0 cells assessed as cell viability after 48 hrs by SRB assay Cytotoxicity against human CL1-0 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 22823514]
Daudi	IC₅₀	0.002 μM Compound: (-)-2	Cytotoxicity against human Burkitt lymphoma, DAUDI cells Cytotoxicity against human Burkitt lymphoma, DAUDI cells	[PMID: 16236503]
DU-145	GI₅₀	1.59 nM Compound: R-cryptopleurine	Anticancer activity against human DU145 cells after 72 hrs by sulforhodamine B assay Anticancer activity against human DU145 cells after 72 hrs by sulforhodamine B assay	[PMID: 21668000]
DU-145	IC₅₀	1.59 nM Compound: cryptopleurine	Cytotoxicity against human DU145 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis Cytotoxicity against human DU145 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis	[PMID: 22823514]
HCT-116	IC₅₀	0.7 nM Compound: (-)-1	Antiproliferative activity against human HCT116 cells after 72 hrs by ATPlite assay Antiproliferative activity against human HCT116 cells after 72 hrs by ATPlite assay	[PMID: 25499434]
HCT-116	IC₅₀	1.04 nM Compound: 2	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 26393416]
HCT-15	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human colon carcinoma, HCT15 cells Cytotoxicity against human colon carcinoma, HCT15 cells	[PMID: 16236503]
HCT-8	GI₅₀	1.09 nM Compound: R-cryptopleurine	Anticancer activity against human HCT8 cells after 72 hrs by sulforhodamine B assay Anticancer activity against human HCT8 cells after 72 hrs by sulforhodamine B assay	[PMID: 21668000]
HCT-8	IC₅₀	1.91 nM Compound: cryptopleurine	Cytotoxicity against human HCT8 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis Cytotoxicity against human HCT8 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis	[PMID: 22823514]
HepG2 2.2.15	IC₅₀	6.3 nM Compound: Cryptopleurine	Cytotoxicity against human HepG2(2.2.15) cells assessed as cell growth inhibition Cytotoxicity against human HepG2(2.2.15) cells assessed as cell growth inhibition	[PMID: 29317151]
HL-60	GI₅₀	<0.001 μM Compound: 36	Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay	[PMID: 22417638]
HT-1376	IC₅₀	0.004 μM Compound: (-)-2	Cytotoxicity against human bladder carcinoma, HT1376 cells Cytotoxicity against human bladder carcinoma, HT1376 cells	[PMID: 16236503]
HUVEC	GI₅₀	11 nM Compound: R-cryptopleurine	Toxicity against HUVEC Toxicity against HUVEC	[PMID: 21668000]
KB	GI₅₀	1.51 nM Compound: R-cryptopleurine	Anticancer activity against human KB cells after 72 hrs by sulforhodamine B assay Anticancer activity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 21668000]
KB	IC₅₀	1.51 nM Compound: cryptopleurine	Cytotoxicity against human KB cells after 2 hrs by methylene blue staining-based spectrophotometric analysis Cytotoxicity against human KB cells after 2 hrs by methylene blue staining-based spectrophotometric analysis	[PMID: 22823514]
KHOS/NP	IC₅₀	0.01 μM Compound: (-)-2	Cytotoxicity against human osteosarcoma, KHOS-NP cells Cytotoxicity against human osteosarcoma, KHOS-NP cells	[PMID: 16236503]
MAT-Ly-Lu	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against rat prostate carcinoma, MatLyLu cells Cytotoxicity against rat prostate carcinoma, MatLyLu cells	[PMID: 16236503]
MCF7	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human breast carcinoma, MCF7 cells Cytotoxicity against human breast carcinoma, MCF7 cells	[PMID: 16236503]
MDA-MB-231	IC₅₀	0.89 nM Compound: 2	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 26393416]
MES-SA	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human uterine sarcoma, MES-SA cells Cytotoxicity against human uterine sarcoma, MES-SA cells	[PMID: 16236503]
MES-SA/Dx5	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human uterine sarcoma, MES-SA-Dx5 cells derived from MES-SA Cytotoxicity against human uterine sarcoma, MES-SA-Dx5 cells derived from MES-SA	[PMID: 16236503]
MRC5	IC₅₀	14 nM Compound: cryptopleurine	Cytotoxicity against human MRC5 cells assessed as cell viability after 48 hrs by SRB assay Cytotoxicity against human MRC5 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 22823514]
NAMALVA	IC₅₀	2.6 nM Compound: (-)-1	Antiproliferative activity against human NAMALWA cells after 72 hrs by ATPlite assay Antiproliferative activity against human NAMALWA cells after 72 hrs by ATPlite assay	[PMID: 25499434]
PA-1	IC₅₀	0.002 μM Compound: (-)-2	Cytotoxicity against human ovarian teratocarcinoma, PA1 cells Cytotoxicity against human ovarian teratocarcinoma, PA1 cells	[PMID: 16236503]
PC-3	IC₅₀	2.55 nM Compound: 2	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 26393416]
PC-9	IC₅₀	5.5 nM Compound: cryptopleurine	Cytotoxicity against human PC9 cells assessed as cell viability after 48 hrs by SRB assay Cytotoxicity against human PC9 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 22823514]
Ramos	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human Burkitt lymphoma, RAMOS cells Cytotoxicity against human Burkitt lymphoma, RAMOS cells	[PMID: 16236503]
SK-HEP1	IC₅₀	0.83 nM Compound: 2	Cytotoxicity against human SKHEP1 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human SKHEP1 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 26393416]
SNU-638	IC₅₀	1.26 nM Compound: 2	Cytotoxicity against human SNU638 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human SNU638 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 26393416]

化学情報

CAS 番号 482-22-4
性状 Solid
分子量 377.48
分子式 C₂₄H₂₇NO₃
Color White to off-white
SMILES

COC1=CC2=C3C=C(C(OC)=CC3=C4C[C@]5(CCCCN5CC4=C2C=C1)[H])OC
別名

(R)-Cryptopleurine; NSC 19912
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (271 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Cai, et al. Phenanthroquinolizidine alkaloids from the roots of Boehmeria pannosa potently inhibit hypoxia-inducible factor-1 in AGS human gastric cancer cells. J. Nat. Prod. 69(7), 1095-1097 (2006).

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量: